FMS Stock Analysis: Fresenius Medical Care | NYSE
Medical Care Facilities | NYSE, USA | Market Cap: 11.113m USD | 12M Return: -19.3% | US3580291066 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 17.3M
EPS Trend: 99.0%
Qual. Beats: 1
Rev. Trend: 21.8%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Fresenius Medical Care AG is a Germany-based, global provider of dialysis care and related products for patients with chronic kidney disease and end-stage renal disease (ESRD). The company operates through two segments: Care Delivery, which runs outpatient dialysis clinics and provides hospital-based dialysis services, and Care Enablement, which manufactures and distributes dialysis machines, dialyzers, concentrates, bloodlines, and related pharmaceuticals. It sells its products directly to clinics and hospitals and through independent distributors and sales agents.
Founded in 1996 and headquartered in Bad Homburg, Fresenius Medical Care is one of the largest vertically integrated players in the dialysis industry, combining clinic operations with its own medical device and pharmaceutical manufacturing. The dialysis services sector is characterized by chronic, recurring treatment cycles that produce stable, reimbursement-driven revenue streams, primarily funded through public programs such as U.S. Medicare and European statutory health insurance systems.
- US Medicare bundled payment adjustments pressure clinic margins
- GLP-1 drug adoption threatens long-term dialysis patient growth
- FME25 cost program targets margin expansion through 2025
| Net Income: 937.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA -0.89 > 1.0 |
| NWC/Revenue: 2.63% < 20% (prev 12.68%; Δ -10.05% < -1%) |
| CFO/TA 0.09 > 3% & CFO 2.80b > Net Income 937.8m |
| Net Debt (12.9b) to EBITDA (3.43b): 3.77 < 3 |
| Current Ratio: 1.07 > 1.5 & < 3 |
| Outstanding Shares: last quarter (539.2m) vs 12m ago -8.12% < -2% |
| Gross Margin: 26.36% > 18% (prev 24.67%; Δ 1.69% > 0.5%) |
| Asset Turnover: 62.08% > 50% (prev 62.38%; Δ -0.29% > 0%) |
| Interest Coverage Ratio: 4.88 > 6 (EBIT TTM 1.87b / Interest Expense TTM 383.0m) |
| A: 0.02 (Total Current Assets 7.69b - Total Current Liabilities 7.18b) / Total Assets 31.3b |
| B: 0.39 (Retained Earnings 12.1b / Total Assets 31.3b) |
| C: 0.06 (EBIT TTM 1.87b / Avg Total Assets 31.3b) |
| D: 0.71 (Book Value of Equity 12.6b / Total Liabilities 17.8b) |
| Altman-Z'' = 2.51 = A |
| DSRI: 1.08 (Receivables 3.47b/3.23b, Revenue 19.4b/19.5b) |
| GMI: 0.94 (GM 24.67% / 26.36%) |
| AQI: 1.03 (AQ_t 0.55 / AQ_t-1 0.53) |
| SGI: 1.00 (Revenue 19.4b / 19.5b) |
| TATA: -0.06 (NI 937.8m - CFO 2.80b) / TA 31.3b) |
| Beneish M = -3.01 (Cap -4..+1) = AA |
As of October 10, 2026, the stock is trading at USD 21.06 with a total of 1,010,172 shares traded. Over the past week, the price has changed by -5.35%, over one month by -5.69%, over three months by -11.92% and over the past year by -19.33%.
Current recommended Stop Loss: 20.40 (which is 3.1% or 1.3 ATR below the current price).
Fresenius Medical Care has received a consensus analysts rating of 2.57. Therefore, it is recommended to hold FMS.
- StrongBuy: 0
- Buy: 1
- Hold: 3
- Sell: 2
- StrongSell: 1
| Analysts Target Price | 23.5 | 11.8% |
Market Cap EUR = 9.91b (11.1b USD * 0.8918200135231 USD.EUR)
P/E Trailing = 10.7629
P/E Forward = 8.5763
P/S = 0.572
P/B = 0.8285
P/EG = 0.7209
Revenue TTM = 19.4b EUR
EBIT TTM = 1.87b EUR
EBITDA TTM = 3.43b EUR
Long Term Debt = 5.82b EUR (from longTermDebt, last quarter)
Short Term Debt = 2.33b EUR (from shortTermDebt, last quarter)
Debt = 14.4b EUR (from shortLongTermDebtTotal, last quarter) + Leases 3.40b
Net Debt = 12.9b EUR (calculated: Debt 14.4b - CCE 1.45b)
Enterprise Value = 22.8b EUR (9.91b + Debt 14.4b - CCE 1.45b)
Interest Coverage Ratio = 4.88 (Ebit TTM 1.87b / Interest Expense TTM 383.0m)
EV/FCF = 12.89x (Enterprise Value 22.8b / FCF TTM 1.77b)
FCF Yield = 7.76% (FCF TTM 1.77b / Enterprise Value 22.8b)
FCF Margin = 9.11% (FCF TTM 1.77b / Revenue TTM 19.4b)
Net Margin = 4.83% (Net Income TTM 937.8m / Revenue TTM 19.4b)
Gross Margin = 26.36% ((Revenue TTM 19.4b - Cost of Revenue TTM 14.3b) / Revenue TTM)
Gross Margin QoQ = 26.95% (prev 25.57%)
Tobins Q-Ratio = 0.73 (Enterprise Value 22.8b / Total Assets 31.3b)
Interest Expense / Debt = 2.67% (Interest Expense 383.0m / Debt 14.4b)
Taxrate = 20.93% (314.2m / 1.50b)
NOPAT = 1.48b (EBIT 1.87b * (1 - 20.93%))
Current Ratio = 1.07 (Total Current Assets 7.69b / Total Current Liabilities 7.18b)
Debt / Equity = 1.14 (Debt 14.4b / totalStockholderEquity, last quarter 12.6b)
Debt / EBITDA = 3.77 (Net Debt 12.9b / EBITDA 3.43b)
Debt / FCF = 7.29 (Net Debt 12.9b / FCF TTM 1.77b)
Total Stockholder Equity = 13.3b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.00% (Net Income 937.8m / Total Assets 31.3b)
RoE = 7.07% (Net Income TTM 937.8m / Total Stockholder Equity 13.3b)
RoCE = 9.80% (EBIT 1.87b / Capital Employed (Equity 13.3b + L.T.Debt 5.82b))
RoIC = 5.80% (NOPAT 1.48b / Invested Capital 25.5b)
WACC = 3.66% (E(9.91b)/V(24.3b) * Re(5.90%) + D(14.4b)/V(24.3b) * Rd(2.67%) * (1-Tc(0.21)))
Discount Rate = 5.90% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -79.59 | Cagr: -3.69%
[DCF] Terminal Value 73.36% ; FCFF base≈1.88b ; Y1≈1.67b ; Y5≈1.39b
[DCF] Fair Price = 17.51 (EV 22.2b - Net Debt 12.9b = Equity 9.32b / Shares 532.2m; r=8.35% [WACC [floored]]; 5y FCF grow -13.56% → 2.50% )
EPS Correlation: 98.98 | EPS CAGR: 30.14% | SUE: 2.32 | # QB: 1
Revenue Correlation: 21.79 | Revenue CAGR: 0.14% | SUE: 0.29 | # QB: 0
EPS current Quarter (2026-09-30): EPS=0.51 | Chg30d=+0.30% | Revisions=-40% | Analysts=2
EPS current Year (2026-12-31): EPS=2.07 | Chg30d=+0.14% | Revisions=-25% | GrowthEPS=-3.3% | GrowthRev=-0.7%
EPS next Year (2027-12-31): EPS=2.66 | Chg30d=-15.55% | Revisions=-25% | GrowthEPS=+28.3% | GrowthRev=+3.2%
[Analyst] Revisions Ratio: -57% (up=0, down=4)